Pharmaceuticals, Biotechnology and Life Sciences
CHICAGO–(BUSINESS WIRE)–Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize…
Provides up to three years of interest only and extension of maturity date CHICAGO–(BUSINESS WIRE)–Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a…
First approval for Xeris is based on positive efficacy and safety results from multiple clinical studies GVOKE is the first…
Findings will support application for European marketing authorization and augment body of data supporting efficacy and utility of its ready-to-use,…
CHICAGO–(BUSINESS WIRE)–Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical
company leveraging its novel technology platforms to develop and
commercialize ready-to-use injectable and infusible drug formulations,
…
Xeris Pharmaceuticals got its third orphane drug designation from the USFDA, this time for its treatment of Hyperinsulinemic Hypoglycemia.